Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

Journal:

The New England Journal of Medicine

Published:

2025-10-30

DOI:

10.1056/nejmoa2508668

Affiliations:

23

Authors:

20

Go to article

Institutions	Authors	Share
AstraZeneca Gaithersburg, MD, United States of America (USA)	2.000000	0.10
Kyungpook National University Chilgok Hospital, South Korea	1.000000	0.05
National Center for Tumor Diseases (NCT) Heidelberg, Germany	1.000000	0.05
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.000000	0.05
HCG Manavata Cancer Centre, India	1.000000	0.05
Harbin Medical University Cancer Hospital, China	1.000000	0.05
Dan L. Duncan Comprehensive Cancer Center, United States of America (USA)	1.000000	0.05
The Fifth Medical Center, PLAGH, China	1.000000	0.05
Samsung Medical Center (SMC), South Korea	1.000000	0.05
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan	1.000000	0.05
Altinbas University, Turkey	1.000000	0.05
Vall d'Hebron University Hospital (HUVH), ICS, Spain	1.000000	0.05
Hospital Brasília, Rede Américas, Brazil	1.000000	0.05
Yıldırım Beyazıt University (YBU), Turkey	1.000000	0.05
AstraZeneca United States, United States of America (USA)	1.000000	0.05
Kanagawa Cancer Center, Japan	1.000000	0.05
Lucen Clínica Oncológica, Argentina	1.000000	0.05
Goethe University Frankfurt (GU), Germany	0.500000	0.03
Sentara Healthcare, United States of America (USA)	0.500000	0.03
German Breast Group GmbH (GBG), Germany	0.500000	0.03
Sarah Cannon Research Institute (SCRI), United States of America (USA)	0.250000	0.01
Virginia Oncology Associates, United States of America (USA)	0.250000	0.01

Interested in Oncology and Carcinogenesis?